Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
We can readily understand why investors are attracted to unprofitable companies. By way of example, Abeona Therapeutics...
Completion of FDA Inspections Marks Progress Towards PDUFA Date
- FDA completed Pre-License Inspection of Abeona’s Cleveland manufacturing facility, as well as inspection of clinical trial sites for pz-cel pivotal Phase 3 VIITAL™ study -CLEVELAND, March 18, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the full year of 2023 and provided an update on progress toward achieving key corporate objectives. Abeona also announced today that the U.S. Food and Drug Administration (FDA) has completed a Pre-License
Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...
CLEVELAND, March 05, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). On February 29, 2024, the Compensation Committee of Abeona’s Board of Directors granted restricted stock equity awards as a material inducement to employment to three individuals hired by Abeona, which equity awards relate to, in t
Steven Cohen (Trades, Portfolio)'s investment firm, Point72 Asset Management, has recently bolstered its portfolio with an additional stake in Abeona Therapeutics Inc (NASDAQ:ABEO). The transaction, which took place on December 31, 2023, saw the firm add 468,670 shares to its holdings in the biopharmaceutical company. This move reflects Cohen's strategic investment decisions and his firm's confidence in the future of Abeona Therapeutics.
Key Insights The considerable ownership by individual investors in Abeona Therapeutics indicates that they collectively...
By David Bautz, PhD NASDAQ:ABEO READ THE FULL ABEO RESEARCH REPORT Business Update FDA Inspection and BLA Mid-Cycle Review Meeting Completed On February 1, 2024, Abeona Therapeutics, Inc. (NASDAQ:ABEO) announced that, as part of the review of the Biologics License Application (BLA) for prademagene zamikeracel (pz-cel; formerly EB-101), the U.S. Food and Drug Administration (FDA) completed both a
- On track for PDUFA target action date of May 25, 2024 - CLEVELAND, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced, as part of the review process by the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for pz-cel (prademagene zamikeracel) for recessive dystrophic epidermolysis bullosa (RDEB), completion by the FDA of both a Bioresearch Monitoring (BIMO) inspection of Abeona and the BLA mid-cycle review meeting. The BI
With the business potentially at an important milestone, we thought we'd take a closer look at Abeona Therapeutics...